Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
58.29 USD | -0.55% |
|
+2.08% | +21.92% |
02-03 | Halozyme Therapeutics Says Non-Small Cell Lung Cancer Treatment Gets Positive Opinion in Europe | MT |
01-16 | Converting IV-drip Medications into Shots | MT |
Capitalization | 7.42B 7.06B 6.66B 5.88B 10.51B 642B 11.66B 79.29B 29.37B 269B 27.8B 27.24B 1,128B | P/E ratio 2024 * |
17.2x | P/E ratio 2025 * | 12.9x |
---|---|---|---|---|---|
Enterprise value | 8.4B 7.99B 7.54B 6.66B 11.9B 727B 13.2B 89.76B 33.26B 304B 31.47B 30.84B 1,277B | EV / Sales 2024 * |
8.37x | EV / Sales 2025 * | 7.25x |
Free-Float |
98.92% | Yield 2024 * |
-
| Yield 2025 * | - |
Last Transcript: Halozyme Therapeutics, Inc.
1 day | -0.55% | ||
1 week | +2.08% | ||
Current month | +2.91% | ||
1 month | +8.29% | ||
3 months | +8.02% | ||
6 months | +1.53% | ||
Current year | +21.92% |







Director | Title | Age | Since |
---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 62 | 2014-01-05 |
Nicole LaBrosse
DFI | Director of Finance/CFO | 42 | 2022-02-01 |
Cortney Caudill
COO | Chief Operating Officer | - | - |
Manager | Title | Age | Since |
---|---|---|---|
Connie Matsui
CHM | Chairman | 71 | 2006-07-30 |
Matthew Posard
BRD | Director/Board Member | 57 | 2013-03-27 |
Helen Torley
BRD | Director/Board Member | 62 | 2014-01-05 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.48% | 0 M€ | -1.80% | - | |
0.73% | 0 M€ | 0.00% | - | |
0.55% | 0 M€ | 0.00% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-0.55% | +2.08% | +66.26% | +73.28% | 7.46B | ||
-0.66% | -2.93% | -11.66% | -22.72% | 62.19B | ||
-1.92% | -2.41% | -25.68% | -28.46% | 7.21B | ||
+0.80% | -1.26% | +44.47% | +57.93% | 6.8B | ||
-1.26% | -8.59% | +98.11% | +139.99% | 6.51B | ||
+0.06% | -12.06% | +22.01% | -11.53% | 2.98B | ||
-1.06% | +1.85% | +41.91% | +29.63% | 2.18B | ||
+0.79% | -1.79% | +30.95% | +27.48% | 2.11B | ||
+0.89% | +1.56% | -36.51% | +48.31% | 1.74B | ||
-.--% | -.--% | - | - | 1.64B | ||
Average | -0.29% | -2.65% | +25.54% | +34.88% | 10.08B | |
Weighted average by Cap. | -0.60% | -3.03% | +6.89% | +4.09% |
2024 * | 2025 * | |
---|---|---|
Net sales | 1B 955M 901M 796M 1.42B 86.91B 1.58B 10.73B 3.97B 36.34B 3.76B 3.68B 153B | 1.18B 1.13B 1.06B 939M 1.68B 103B 1.86B 12.66B 4.69B 42.9B 4.44B 4.35B 180B |
Net income | 438M 417M 393M 347M 620M 37.94B 689M 4.68B 1.73B 15.86B 1.64B 1.61B 66.59B | 579M 551M 519M 459M 820M 50.12B 910M 6.19B 2.29B 20.96B 2.17B 2.13B 87.98B |
Net Debt | 980M 933M 880M 777M 1.39B 84.9B 1.54B 10.48B 3.88B 35.5B 3.67B 3.6B 149B | 1.17B 1.11B 1.05B 925M 1.65B 101B 1.83B 12.46B 4.62B 42.23B 4.37B 4.28B 177B |
Date | Price | Change | Volume |
---|---|---|---|
25-02-14 | 58.29 $ | -0.55% | 1,000,607 |
25-02-13 | 58.61 $ | +0.86% | 883,155 |
25-02-12 | 58.11 $ | +1.36% | 888,174 |
25-02-11 | 57.33 $ | -0.02% | 1,143,602 |
25-02-10 | 57.34 $ | +0.42% | 967,321 |
Delayed Quote Nasdaq, February 14, 2025 at 04:00 pm
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HALO Stock

MarketScreener is also available in this country: United States.
Switch edition